Trial Profile
Assessment of the Effect of 480 mg and 1200 mg of BI 201335 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Four-way Crossover Phase-I-study With Moxifloxacin as Positive Control
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Faldaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 16 Jul 2014 New trial record